Cargando…

Pembrolizumab-Induced Myasthenia Gravis: A Case Report and Review of the Literature

Myasthenia gravis (MG) is one of the most common neuromuscular adverse effects of immune checkpoint inhibitors (ICIs) and can result in significant morbidity and mortality when it affects the bulbar and respiratory muscles. Diagnosing immune-related MG (irMG) is challenging due to its nonspecific pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Eglenen Polat, Buse, Safi, Danish, Hafez, Maria, Kamran, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378713/
https://www.ncbi.nlm.nih.gov/pubmed/37519591
http://dx.doi.org/10.7759/cureus.41087
Descripción
Sumario:Myasthenia gravis (MG) is one of the most common neuromuscular adverse effects of immune checkpoint inhibitors (ICIs) and can result in significant morbidity and mortality when it affects the bulbar and respiratory muscles. Diagnosing immune-related MG (irMG) is challenging due to its nonspecific presentation and high negativity rate for MG antibody markers. Patients, primary care providers, and emergency care providers should be educated about MG as a potential adverse effect of ICIs for timely diagnosis and intervention.